A phase 1 clinical trial of ATL-201 for KCNT1-related epilepsy
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs ATL-201-Atalanta-Therapeutics (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- 04 Feb 2025 New trial record
- 28 Jan 2025 According to an EQT Life Sciences media release, USD 75 million Series B financing will support Phase 1 clinical trials of the company's investigational RNAi therapies for KCNT1-related epilepsy and Huntington's disease.
- 28 Jan 2025 According to an Atalanta Therapeutics media release, company is progressing programs toward IND submissions this year to start Phase 1 trials for epilepsy and Huntington's disease